Hillsdale Investment Management Inc. Has $5.52 Million Stock Position in Mirum Pharmaceuticals, Inc. $MIRM

Hillsdale Investment Management Inc. boosted its stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 25.4% during the 1st quarter, HoldingsChannel.com reports. The fund owned 59,730 shares of the company’s stock after acquiring an additional 12,100 shares during the period. Hillsdale Investment Management Inc.’s holdings in Mirum Pharmaceuticals were worth $5,518,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the company. Cullen Frost Bankers Inc. bought a new position in Mirum Pharmaceuticals during the 4th quarter worth approximately $30,000. Eurizon Capital SGR S.p.A. acquired a new position in shares of Mirum Pharmaceuticals in the 4th quarter worth approximately $32,000. CIBC Private Wealth Group LLC bought a new stake in shares of Mirum Pharmaceuticals in the 4th quarter valued at $32,000. Quantbot Technologies LP bought a new stake in shares of Mirum Pharmaceuticals in the 3rd quarter valued at $33,000. Finally, Comerica Bank increased its position in shares of Mirum Pharmaceuticals by 45.1% during the first quarter. Comerica Bank now owns 895 shares of the company’s stock worth $40,000 after buying an additional 278 shares during the period.

Insider Buying and Selling

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 2,721 shares of the stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $120.00, for a total value of $326,520.00. Following the transaction, the senior vice president owned 3,114 shares in the company, valued at approximately $373,680. This represents a 46.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher Peetz sold 30,000 shares of the stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $95.84, for a total value of $2,875,200.00. Following the completion of the transaction, the chief executive officer owned 194,309 shares in the company, valued at approximately $18,622,574.56. The trade was a 13.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 65,315 shares of company stock valued at $6,991,928. 8.32% of the stock is owned by company insiders.

Mirum Pharmaceuticals Price Performance

Shares of NASDAQ MIRM opened at $120.89 on Wednesday. The firm’s 50-day moving average price is $107.23 and its 200-day moving average price is $98.40. Mirum Pharmaceuticals, Inc. has a 1-year low of $50.25 and a 1-year high of $130.00. The firm has a market capitalization of $7.37 billion, a P/E ratio of -8.88 and a beta of 0.48. The company has a current ratio of 2.09, a quick ratio of 1.99 and a debt-to-equity ratio of 1.28.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($13.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($12.68). The company had revenue of $159.88 million for the quarter, compared to the consensus estimate of $148.21 million. Mirum Pharmaceuticals had a negative return on equity of 11.28% and a negative net margin of 140.24%.Mirum Pharmaceuticals’s revenue for the quarter was up 43.3% compared to the same quarter last year. During the same period last year, the company earned ($0.30) EPS. Equities research analysts anticipate that Mirum Pharmaceuticals, Inc. will post -2.01 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on MIRM. Robert W. Baird lifted their target price on shares of Mirum Pharmaceuticals from $112.00 to $129.00 and gave the stock an “outperform” rating in a research note on Thursday, May 7th. Wall Street Zen cut shares of Mirum Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Royal Bank Of Canada increased their price target on Mirum Pharmaceuticals from $142.00 to $148.00 and gave the stock an “outperform” rating in a report on Tuesday, July 7th. Citigroup reissued an “outperform” rating on shares of Mirum Pharmaceuticals in a research report on Monday, June 15th. Finally, CLSA set a $146.00 price objective on Mirum Pharmaceuticals in a research note on Monday, June 15th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Mirum Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $143.40.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.